Viralym-B

About BK Virus (BKV)

  • BKV-associated hemorrhagic cystitis in HSCT recipients is associated with incapacitating pain, significant blood loss, clot retention and renal failure
  • Currently, there are no FDA-approved drugs for treatment of BKV infection and disease.

Viralym-B

Viralym-B (virus-specific lymphocytes against BKV) is a “ready to administer” T cell immunotherapy product made up of a generated bank of third-party, partially HLA-matched BKV-directed T cells that have been activated from exposure to BKV. Our Phase 1 clinical trial of Viralym-B is not yet open for participant recruitment. To learn more, please visit ClincialTrials.gov: NCT02313844

ClincialTrials.gov: NCT02313844